Functional drug sensitivity testing exposes biological replicas of a patient’s tumor (3D-microtumors) to drugs directly. This approach provides functional data that capture information on key tumor vulnerabilities, including those derived from altered epigenetic states or altered signaling pathways not necessarily driven by genomic anomalies. It is, therefore, the best option to guide therapy selection in the absence of biomarkers. CE-marked, and therefore approved and actionable immediately in clinical settings, the IndiTreat® family of products supports therapy decision-making in metastatic colorectal cancer and sets the stage for innovation and truly personalized management of patients. North America 10% Latin America 7% Africa 3% Europe 27% Asia 52% Oceania 1% 1 Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. doi: 10.5114/pg.2018.81072. Epub 2019 Jan 6. PMID: 31616522; PMCID: PMC6791134, 2 Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al.: The global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut, Published online 8 September 2022 - http://dx.doi. org/10.1136/gutjnl-2022-327736, 3 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69–90. https://doi. org/10.3322/caac.20107 PMID: 21296855, 4 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–674. https://doi.org/10.1016/j. cell.2011.02.013 PMID: 21376230, 5 Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014; 35(1):41–50. https://doi.org/10.1016/j.tips.2013.11.004 PMID: 24361003 Global distribution of new mCRC cases IndiTreat® pre-evaluates the impact of drugs for which there are no biomarkers on individual patients’ microtumors.
RkJQdWJsaXNoZXIy ODY1MjQ=